In the negotiation for the current agreements, which will expire in mid-2027, one target was off-patent originator biologics that had not seen any meaningful price disclosure reductions. The Government and its officials might have new targets in the upcoming negotiation. …
Australia's next industry agreements might put more biologics squarely in the frame
June 26, 2026 Latest NewsBioPharmaComment
Latest Video
New Stories
-
If this is an example of a bully playing hardball, it's not the companies
July 21, 2026 - - Latest News -
LTR Pharma secures national US manufacturing and fulfilment partner
July 21, 2026 - - Latest News -
Candidate shows antidepressant signal in difficult to treat depression
July 21, 2026 - - Latest News -
'Our access. Our medicines. Our vaccines. Our medical technology'
July 21, 2026 - - Latest News -
Novartis names Anne Harris to lead Australia and New Zealand
July 20, 2026 - - Latest News -
Why is the system slower than when there was no patient involvement or input?
July 20, 2026 - - Latest News -
No company in its right mind would risk a large private market for this outcome?
July 20, 2026 - - Latest News